Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study.
BACKGROUND
Epidermal growth factor receptor inhibitors are widely prescribed anticancer drugs. Patients treated commonly develop dermatologic adverse drugs reactions, but rarely they are involved in systematic evaluation of their quality of life. This monocentric cross sectional study is carried out to assess quality of life in colon cancer patients experienced skin side effects due to anti epidermal growth factor receptor inhibitors therapy.


METHODS
Consecutive patients with skin side effects to therapy treated at Fondazione Poliambulanza were enrolled in this study. Quality of life was evaluated with the Italian validated version of Skindex-29 questionnaire, exploring three dimensions: symptoms, emotional, and physical functioning. Skindex-29 was administered one time between the eighth and the twelfth week of the treatment.


RESULTS
Forty-five consecutive patients, mainly with metastatic colon cancer (29 female, 16 male), with an average age of 59.31 years (ranging from 34-78) were included in the study and analyzed. Patients showed a great impact of skin side effects on symptoms (mean 43), followed by emotional (mean 30), and functioning (mean 26) scales. In general women, the 55-65 age class, and patients with partial remission reported the worst quality of life.


CONCLUSIONS
Epidermal growth factor receptor inhibitors' skin side effects have an important impact on quality of life in advanced colon cancer patients; symptoms scale is the most effect respect to emotional and functioning scales.
Andreis
Federica
F
UO di Oncologia Medica, Fondazione Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy.
Rizzi
Anna
A
Mosconi
Paola
P
Braun
Claudia
C
Rota
Luigina
L
Meriggi
Fausto
F
Mazzocchi
Maria
M
Zaniboni
Alberto
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000150:complications* / Q000188:drug therapy; D003430:Cross-Sectional Studies; D003875:Drug Eruptions / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents; D066246:ErbB Receptors
Skin Pharmacol Physiol. 2007;20(5):260-2
17641540
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):34-6
18154217
J Invest Dermatol. 1996 Nov;107(5):707-13
8875954
Arch Dermatol. 1998 Apr;134(4):454-8
9554297
Cancer. 2009 Apr 1;115(7):1544-54
19189371
Arch Dermatol. 2005 Mar;141(3):325-30
15781673
Arch Dermatol. 1997 Nov;133(11):1433-40
9371029
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):10-6
18154213
Oncology (Williston Park). 2009 Feb;23(2):186-94
19323301
Anticancer Drugs. 2006 Nov;17(10):1227-9
17075324
Support Care Cancer. 2010 Mar;18(3):329-34
19484487
J Invest Dermatol. 2007 Dec;127(12):2726-39
17989733
J Clin Oncol. 2009 Apr 10;27(11):1822-8
19273701
J Invest Dermatol. 1997 Jan;108(1):103-7
8980297
Br J Dermatol. 2009 Apr;160(4):815-22
19120325
Dermatology. 2002;204(1):43-9
11834849
Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S40-6
17520580
Clin Colorectal Cancer. 2008 Mar;7(2):144-8
18501075
J Clin Oncol. 2010 Mar 10;28(8):1351-7
20142600